1
|
Ţînţaş ML, Peauger L, Barré A, Papamicaël C, Besson T, Sopkovà-de Oliveira Santos J, Gembus V, Levacher V. Design, synthesis and preliminary biological evaluation of rivastigmine-INDY hybrids as multitarget ligands against Alzheimer's disease by targeting butyrylcholinesterase and DYRK1A/CLK1 kinases. RSC Med Chem 2024; 15:963-980. [PMID: 38516603 PMCID: PMC10953492 DOI: 10.1039/d3md00708a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Accepted: 02/16/2024] [Indexed: 03/23/2024] Open
Abstract
Based on a multitarget approach implementing rivastigmine-INDY hybrids 1, we identified a set of pseudo-irreversible carbamate-type inhibitors of eqBuChE that, after carbamate transfer at the active site serine residue, released the corresponding INDY analogues 2 endowed with hDYRK1A/hCLK1 kinases inhibitory properties. A SAR study and molecular docking investigation of both series of compounds 1 and 2 revealed that appropriate structural modifications at the carbamate moiety and at the N-appendage of the benzothiazole core led to potent and selective eqBuChE inhibitors with IC50 up to 27 nM and potent hDYRK1A and hCLK1 inhibitors with IC50 up to 106 nM and 17 nM respectively. Pleasingly, identification of the matched pair of compounds 1b/2b with a good balance between inhibition of eqBuChE and hDYRK1A/hCLK1 kinases (IC50 = 68 nM and IC50 = 529/54 nM, respectively) further validated our multitarget approach based on a sequential mechanism of action. In addition, target compound 1b exhibited a suitable ADMET profile, including good brain permeability and high stability in PBS, encouraging further biological investigation as a drug candidate.
Collapse
Affiliation(s)
- Mihaela-Liliana Ţînţaş
- INSA Rouen Normandie, Univ Rouen Normandie, CNRS, COBRA UMR 6014, Normandie Univ INC3M FR 3038 F-76000 Rouen France
| | | | - Anaïs Barré
- INSA Rouen Normandie, Univ Rouen Normandie, CNRS, COBRA UMR 6014, Normandie Univ INC3M FR 3038 F-76000 Rouen France
| | - Cyril Papamicaël
- INSA Rouen Normandie, Univ Rouen Normandie, CNRS, COBRA UMR 6014, Normandie Univ INC3M FR 3038 F-76000 Rouen France
| | - Thierry Besson
- INSA Rouen Normandie, Univ Rouen Normandie, CNRS, COBRA UMR 6014, Normandie Univ INC3M FR 3038 F-76000 Rouen France
| | - Jana Sopkovà-de Oliveira Santos
- UNICAEN, CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie), Normandie Univ. Bd Becquerel F-14032 Caen France
| | - Vincent Gembus
- VFP Therapies 15 rue François Couperin 76000 Rouen France
| | - Vincent Levacher
- INSA Rouen Normandie, Univ Rouen Normandie, CNRS, COBRA UMR 6014, Normandie Univ INC3M FR 3038 F-76000 Rouen France
| |
Collapse
|
2
|
Carey-Smith SL, Simad MH, Panchal K, Aya-Bonilla C, Smolders H, Lin S, Armitage JD, Nguyen VT, Bentley K, Ford J, Singh S, Oommen J, Laurent AP, Mercher T, Crispino JD, Montgomery AP, Kassiou M, Besson T, Deau E, Meijer L, Cheung LC, Kotecha RS, Malinge S. Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia. Haematologica 2024. [PMID: 38426275 DOI: 10.3324/haematol.2023.284271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Indexed: 03/02/2024] Open
Abstract
Not available.
Collapse
Affiliation(s)
- Shannon L Carey-Smith
- Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA, Australia; Curtin Medical School, Curtin University, Perth, WA
| | - Maryam H Simad
- Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA
| | - Kunjal Panchal
- Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA, Australia; Curtin Medical School, Curtin University, Perth, WA
| | | | - Hannah Smolders
- Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA
| | - Sang Lin
- Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA
| | | | - Vivien T Nguyen
- Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA
| | - Kathryn Bentley
- Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA
| | - Jette Ford
- Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA
| | - Sajla Singh
- Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA
| | - Joyce Oommen
- Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA
| | | | | | - John D Crispino
- Department of Hematology, St Jude Children's Hospital, Memphis, TN
| | | | | | - Thierry Besson
- University Rouen Normandie, INSA Rouen Normandie, CNRS, COBRA UMR 6014, 76000
| | | | | | - Laurence C Cheung
- Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA, Australia; Curtin Medical School, Curtin University, Perth, WA, Australia; Curtin Health Innovation Research Institute, Curtin University, Perth, WA
| | - Rishi S Kotecha
- Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA, Australia; Curtin Medical School, Curtin University, Perth, WA, Australia; Department of Clinical Haematology, Oncology, Blood and Marrow Transplantation, Perth Children's Hospital, Perth, WA, Australia; University of Western Australia, Perth, WA
| | - Sébastien Malinge
- Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA, Australia; Curtin Medical School, Curtin University, Perth, WA, Australia; University of Western Australia, Perth, WA.
| |
Collapse
|
3
|
Delouche T, Gadiry-Diallo A, Besson T, Ogoshi S, Fruit C. Photocatalyst-Free Visible Light-Mediated C-H Perfluoroalkylation of Quinazolin-4(3H)-ones with perfluoroalkyl iodides. SYNTHESIS-STUTTGART 2023. [DOI: 10.1055/a-2054-0482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023]
Abstract
A practical and sustainable photocatalyst-free protocol for photo-induced synthesis of perfluoroalkylated quinazolin-4(3H)-ones is described starting from quinazolin-4(3H)-ones. A wide range of substituted or fused-quinazolinones is found to be compatible, providing the corresponding mono- and bis-perfluoroalkylated compounds in moderate yields. This visible-light mediated C-H perfluoroalkylation allows an environmentally friendly and straightforward access to an array of unprecedented functionalized quinazolinone scaffolds, presenting attractive features for drug discovery. The control experiments demonstrated that a radical mechanism is involved in the reaction mechanism.
Collapse
Affiliation(s)
- Thomas Delouche
- COBRA, UMR 6014, Normandie Univ; Uni Rouen; INSA; CNRS, Mont St Aignan Cedex, France
| | - Abdoul Gadiry-Diallo
- COBRA, UMR 6014, Normandie Univ; Uni Rouen; INSA; CNRS, Mont St Aignan Cedex, France
| | - Thierry Besson
- CNRS UMR 6014 - COBRA, Université de Rouen, Mont Saint Aignan, France
| | | | - Corinne Fruit
- COBRA, UMR 6014, Normandie Univ; Uni Rouen; INSA; CNRS, Mont St Aignan Cedex, France
| |
Collapse
|
4
|
Perrin TP, Morio CYM, Besson T, Kerhervé HA, Millet GY, Rossi J. Comparison of skin and shoe marker placement on metatarsophalangeal joint kinematics and kinetics during running. J Biomech 2023; 146:111410. [PMID: 36529092 DOI: 10.1016/j.jbiomech.2022.111410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Revised: 11/28/2022] [Accepted: 12/01/2022] [Indexed: 12/12/2022]
Abstract
This study investigated the effects of marker placement (skin- vs shoe-mounted) on metatarsophalangeal joint (MTP) kinematics and kinetics during running. Fifteen trained men ran on a 15-m track at 10 and 13 km/h with three (low, standard and high stiffness) shoe longitudinal bending stiffnesses (LBS). Reflective markers were fixed on the shoe upper, and on the skin using holes cut in the shoe. Three-dimensional marker positions and ground reaction forces were recorded at 200 and 2000 Hz, respectively. Kinematic and kinetic parameters were analyzed using one-dimensional metrics (statistical parametric mapping). MTP joint was less dorsiflexed at midstance ([57% to 100%] of braking phase and [0% to 48%] of pushing phase), and the MTP joint plantarflexion moment was higher ([22% to 55%] of pushing phase) with the shoe markerset in comparison with the skin markerset. The effect of LBS on MTP angle was found to be significant for a larger percentage of each stride using the shoe markerset compared to the skin markerset. However, the effect of LBS on plantarflexion moment was significant with the shoe markerset only. The effect of running speed on MTP angle was significant for a larger percentage of each stride with the skin markerset. This study demonstrates that the placement of markers influences the measurement of MTP kinematics and kinetics and that these effects are mediated by other variables such as LBS or running speed. It is concluded that the shoe markerset does not fully reflect the movement of the MTP joint.
Collapse
Affiliation(s)
- T P Perrin
- Univ Lyon, UJM-Saint-Etienne, Inter-university Laboratory of Human Movement Biology, EA 7424, F-42023 Saint-Etienne, France; ENS Rennes, Bruz, France
| | - C Y M Morio
- Decathlon SportsLab, Movement Sciences Department, Lille, France
| | - T Besson
- Univ Lyon, UJM-Saint-Etienne, Inter-university Laboratory of Human Movement Biology, EA 7424, F-42023 Saint-Etienne, France
| | - H A Kerhervé
- Univ Rennes, M2S - EA 7470, F-35000 Rennes, France
| | - G Y Millet
- Univ Lyon, UJM-Saint-Etienne, Inter-university Laboratory of Human Movement Biology, EA 7424, F-42023 Saint-Etienne, France; Institut Universitaire de France (IUF), France
| | - J Rossi
- Univ Lyon, UJM-Saint-Etienne, Inter-university Laboratory of Human Movement Biology, EA 7424, F-42023 Saint-Etienne, France.
| |
Collapse
|
5
|
Ţînţaş ML, Peauger L, Alix F, Papamicaël C, Besson T, Sopková-de Oliveira Santos J, Gembus V, Levacher V. Straightforward Access to a New Class of Dual DYRK1A/CLK1 Inhibitors Possessing a Simple Dihydroquinoline Core. Molecules 2022; 28:molecules28010036. [PMID: 36615235 PMCID: PMC9822041 DOI: 10.3390/molecules28010036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Revised: 12/16/2022] [Accepted: 12/19/2022] [Indexed: 12/24/2022]
Abstract
The DYRK (Dual-specificity tyrosine phosphorylation-regulated kinase) family of protein kinases is involved in the pathogenesis of several neurodegenerative diseases. Among them, the DYRK1A protein kinase is thought to be implicated in Alzheimer's disease (AD) and Down syndrome, and as such, has emerged as an appealing therapeutic target. DYRKs are a subset of the CMGC (CDK, MAPKK, GSK3 and CLK) group of kinases. Within this group of kinases, the CDC2-like kinases (CLKs), such as CLK1, are closely related to DYRKs and have also sparked great interest as potential therapeutic targets for AD. Based on inhibitors previously described in the literature (namely TG003 and INDY), we report in this work a new class of dihydroquinolines exhibiting inhibitory activities in the nanomolar range on hDYRK1A and hCLK1. Moreover, there is overwhelming evidence that oxidative stress plays an important role in AD. Pleasingly, the most potent dual kinase inhibitor 1p exhibited antioxidant and radical scavenging properties. Finally, drug-likeness and molecular docking studies of this new class of DYRK1A/CLK1 inhibitors are also discussed in this article.
Collapse
Affiliation(s)
- Mihaela-Liliana Ţînţaş
- INSA Rouen Normandie, Univ. Rouen Normandie, CNRS UMR 6014 COBRA, FR 3038, F-76000 Rouen, France
| | - Ludovic Peauger
- VFP Therapies, 15 rue François Couperin, 76000 Rouen, France
| | - Florent Alix
- VFP Therapies, 15 rue François Couperin, 76000 Rouen, France
| | - Cyril Papamicaël
- INSA Rouen Normandie, Univ. Rouen Normandie, CNRS UMR 6014 COBRA, FR 3038, F-76000 Rouen, France
- Correspondence: (C.P.); (V.G.); (V.L.); Tel.: +33-023-552-2485 (V.L.)
| | - Thierry Besson
- INSA Rouen Normandie, Univ. Rouen Normandie, CNRS UMR 6014 COBRA, FR 3038, F-76000 Rouen, France
| | - Jana Sopková-de Oliveira Santos
- UNICAEN, CERMN (Centre d’Etudes et de Recherche sur le Médicament de Normandie), Normandie Univ., Bd Becquerel, F-14032 Caen, France
| | - Vincent Gembus
- VFP Therapies, 15 rue François Couperin, 76000 Rouen, France
- Correspondence: (C.P.); (V.G.); (V.L.); Tel.: +33-023-552-2485 (V.L.)
| | - Vincent Levacher
- INSA Rouen Normandie, Univ. Rouen Normandie, CNRS UMR 6014 COBRA, FR 3038, F-76000 Rouen, France
- Correspondence: (C.P.); (V.G.); (V.L.); Tel.: +33-023-552-2485 (V.L.)
| |
Collapse
|
6
|
Broudic N, Pacheco-Benichou A, Fruit C, Besson T. Synthesis of 2-Cyanobenzothiazoles via Pd-Catalyzed/Cu-Assisted C-H Functionalization/Intramolecular C-S Bond Formation from N-Arylcyanothioformamides. Molecules 2022; 27:molecules27238426. [PMID: 36500519 PMCID: PMC9738468 DOI: 10.3390/molecules27238426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 11/21/2022] [Accepted: 11/24/2022] [Indexed: 12/04/2022]
Abstract
We report herein on a catalytic system involving palladium and copper to achieve the cyclization of N-arylcyanothioformamides and the synthesis of 2-cyanobenzothiazoles. The C-H functionalization/intramolecular C-S bond formation reaction was achieved in the presence of air, using 2.0 equiv of an inorganic additive (KI). In many cases, the reaction led to a sole product regioselectively obtained in good yields, allowing the synthesis of a wide range of substituted 2-cyanobenzothiazole derivatives, providing valuable building blocks for the design of more complex heterocyclic or molecular labeling systems.
Collapse
|
7
|
Elagib KE, Brock A, Clementelli CM, Mosoyan G, Delehanty LL, Sahu RK, Pacheco-Benichou A, Fruit C, Besson T, Morris SW, Eto K, Jobaliya C, French DL, Gadue P, Singh S, Shi X, Qin F, Cornelison R, Li H, Iancu-Rubin C, Goldfarb AN. Relieving Dyrk1a repression of MKL1 confers an adult-like phenotype to human infantile megakaryocytes. J Clin Invest 2022; 132:154839. [PMID: 35925681 PMCID: PMC9525118 DOI: 10.1172/jci154839] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Accepted: 08/02/2022] [Indexed: 11/30/2022] Open
Abstract
Infantile (fetal and neonatal) megakaryocytes (Mks) have a distinct phenotype consisting of hyperproliferation, limited morphogenesis, and low platelet production capacity. These properties contribute to clinical problems that include thrombocytopenia in neonates, delayed platelet engraftment in recipients of cord blood stem cell transplants, and inefficient ex vivo platelet production from pluripotent stem cell–derived Mks. The infantile phenotype results from deficiency of the actin-regulated coactivator, MKL1, which programs cytoskeletal changes driving morphogenesis. As a strategy to complement this molecular defect, we screened pathways with the potential to affect MKL1 function and found that DYRK1A inhibition dramatically enhanced Mk morphogenesis in vitro and in vivo. Dyrk1 inhibitors rescued enlargement, polyploidization, and thrombopoiesis in human neonatal Mks. Mks derived from induced pluripotent stem cells responded in a similar manner. Progenitors undergoing Dyrk1 inhibition demonstrated filamentous actin assembly, MKL1 nuclear translocation, and modulation of MKL1 target genes. Loss-of-function studies confirmed MKL1 involvement in this morphogenetic pathway. Expression of Ablim2, a stabilizer of filamentous actin, increased with Dyrk1 inhibition, and Ablim2 knockdown abrogated the actin, MKL1, and morphogenetic responses to Dyrk1 inhibition. These results delineate a pharmacologically tractable morphogenetic pathway whose manipulation may alleviate clinical problems associated with the limited thrombopoietic capacity of infantile Mks.
Collapse
Affiliation(s)
- Kamaleldin E Elagib
- Department of Pathology, University of Virginia School of Medicine, Charlottesville, United States of America
| | - Ashton Brock
- Department of Pathology, University of Virginia School of Medicine, Charlottesville, United States of America
| | - Cara M Clementelli
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - Gohar Mosoyan
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - Lorrie L Delehanty
- Department of Pathology, University of Virginia School of Medicine, Charlottesville, United States of America
| | - Ranjit K Sahu
- Department of Pathology, University of Virginia School of Medicine, Charlottesville, United States of America
| | | | | | | | - Stephan W Morris
- Medical Oncology, Memphis Bioworks Foundation, Memphis, United States of America
| | - Koji Eto
- Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
| | - Chintan Jobaliya
- Center of Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, United States of America
| | - Deborah L French
- Center of Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, United States of America
| | - Paul Gadue
- Center of Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, United States of America
| | - Sandeep Singh
- Department of Pathology, University of Virginia School of Medicine, Charlottesville, United States of America
| | - Xinrui Shi
- Department of Pathology, University of Virginia School of Medicine, Charlottesville, United States of America
| | - Fujun Qin
- Academy of Medical Sciences, Zhengzhou University, Henan, China
| | - Robert Cornelison
- Department of Pathology, University of Virginia School of Medicine, Charlottesville, United States of America
| | - Hui Li
- Department of Pathology, University of Virginia School of Medicine, Charlottesville, United States of America
| | - Camelia Iancu-Rubin
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - Adam N Goldfarb
- Department of Pathology, University of Virginia School of Medicine, Charlottesville, United States of America
| |
Collapse
|
8
|
Wolf B, Piksa M, Beley I, Patoux A, Besson T, Cordier V, Voedisch B, Schindler P, Stöllner D, Perrot L, von Gunten S, Brees D, Kammüller M. Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity. Immunology 2022; 166:380-407. [PMID: 35416297 DOI: 10.1111/imm.13481] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Revised: 02/01/2022] [Accepted: 02/23/2022] [Indexed: 11/30/2022] Open
Abstract
In this study we show that glycosylation is relevant for immune recognition of therapeutic antibodies, and that defined glycan structures can modulate immunogenicity. Concerns regarding immunogenicity arise from the high heterogeneity in glycosylation that is difficult to control and can deviate from human glycosylation if produced in non-human cell lines. While non-human glycosylation is thought to cause hypersensitivity reactions and immunogenicity, less is known about effects of Fc-associated glycan structures on immune cell responses. We postulated that glycosylation influences antigen recognition and subsequently humoral responses to therapeutic antibodies by modulating 1) recognition and uptake by dendritic cells (DCs), and 2) antigen routing, processing and presentation. Here, we compared different glycosylation variants of the antibody rituximab (RTX) in in vitro assays using human DCs and T cells as well as in in vivo studies. We found that human DCs bind and internalize unmodified RTX stronger compared to its aglycosylated form suggesting that glycosylation mediates uptake after recognition by glycan-specific receptors. Furthermore, we show that DC-uptake of RTX increases or decreases if glycosylation is selectively modified to recognize activating (by mannosylation) or inhibitory lectin receptors (by sialylation). Moreover, glycosylation seems to influence antigen presentation by DCs because specific glycovariants tend to induce either stronger or weaker T cell activation. Finally, we demonstrate that antibody glycosylation impacts anti-drug antibody (ADA) responses to RTX in vivo. Hence, defined glycan structures can modulate immune recognition and alter ADA responses. Glyco-engineering may help to decrease clinical immunogenicity and ADA-associated adverse events such as hypersensitivity reactions.
Collapse
Affiliation(s)
- Babette Wolf
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Mateusz Piksa
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Isabelle Beley
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Agnes Patoux
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Thierry Besson
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Valerie Cordier
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Bernd Voedisch
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | | | | | - Ludovic Perrot
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | | | - Dominique Brees
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | | |
Collapse
|
9
|
Campos JF, Besson T, Berteina-Raboin S. Review on the Synthesis and Therapeutic Potential of Pyrido[2,3-d], [3,2-d], [3,4-d] and [4,3-d]pyrimidine Derivatives. Pharmaceuticals (Basel) 2022; 15:ph15030352. [PMID: 35337149 PMCID: PMC8949896 DOI: 10.3390/ph15030352] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 03/03/2022] [Accepted: 03/10/2022] [Indexed: 12/10/2022] Open
Abstract
The objective of this review is to list the structures composed of a pyridopyrimidine moiety which have shown a therapeutic interest or have already been approved for use as therapeutics. We consider all the synthetic protocols to prepare these pyridopyrimidine derivatives. The review is organized into four sections, successively pyrido[2,3-d]pyrimidines, pyrido[3,4-d]pyrimidines, pyrido[4,3-d]pyrimidines and pyrido[3,2-d]pyrimidines. For each compound we present the biological activity and the synthetic route reported. To produce this manuscript, the bibliographic research was done using Reaxys and Scifinder for each kind of pyridopyrimidine.
Collapse
Affiliation(s)
- Joana F. Campos
- Institut de Chimie Organique et Analytique (ICOA), Université d’Orléans CNRS, ICOA UMR 7311, BP 6759, Rue de Chartres, CEDEX 2, 45067 Orléans, France;
| | - Thierry Besson
- Université de Rouen-Normandie (UNIROUEN), INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France;
| | - Sabine Berteina-Raboin
- Institut de Chimie Organique et Analytique (ICOA), Université d’Orléans CNRS, ICOA UMR 7311, BP 6759, Rue de Chartres, CEDEX 2, 45067 Orléans, France;
- Correspondence: ; Tel.: +33-238-494-856
| |
Collapse
|
10
|
Decombat C, Duval O, Besson T, Bourel L, Pudlo M. A skills framework integrating professionally relevant medicinal chemistry proficiencies to strengthen the contemporary practice of pharmacy. Ann Pharm Fr 2021; 80:176-186. [PMID: 34314680 DOI: 10.1016/j.pharma.2021.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 06/18/2021] [Accepted: 07/19/2021] [Indexed: 11/26/2022]
Abstract
OBJECTIVE Our aim was to define a repository of competences in Medicinal Chemistry, to be developed during Pharmacy studies and expected in professional practices, while highlighting the fundamental character of the subject and its interdisciplinary links within the Pharmaceutical Sciences. METHODS A first version, based on both our professional and educational experience, consolidated by a review of educational articles and good practice guidelines, was obtained by following a competency-based approach. It was then completed by Medicinal Chemistry teachers in various French Pharmacy Faculties to obtain a comprehensive data set. The final version was reviewed in the light of relevant comments from 15 experts from related disciplines. RESULTS A comprehensive competency framework with extensive practical applications was developed. CONCLUSIONS This pilot study provides a teaching repository for medicinal chemistry for use by teachers of medicinal sciences. It highlights the fundamental role of the discipline within Pharmacy studies and provides links with professional practices. This repository will be useful to various teaching teams in a context of integrated disciplines and could be replicated in related disciplines.
Collapse
Affiliation(s)
- C Decombat
- AFECT Association française des Enseignants de Chimie Thérapeutique (French Association of Medicinal Chemistry Teachers), Paris, France; Université Clermont-Auvergne, INRA, UNH, Unité de Nutrition Humaine, CRNH Auvergne, 63000 Clermont-Ferrand, France
| | - O Duval
- AFECT Association française des Enseignants de Chimie Thérapeutique (French Association of Medicinal Chemistry Teachers), Paris, France; MINT - UMR INSERM U1066/UMR CNRS 6021, IBS-CHU ANGERS, 4, rue Larrey, 49933 Angers cedex 9, France
| | - T Besson
- AFECT Association française des Enseignants de Chimie Thérapeutique (French Association of Medicinal Chemistry Teachers), Paris, France; Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France
| | - L Bourel
- AFECT Association française des Enseignants de Chimie Thérapeutique (French Association of Medicinal Chemistry Teachers), Paris, France; UMR 7199 CNRS/Unistra, 3Bio team/ITI InnoVec, Faculté de Pharmacie, 74, route du Rhin, 67400 Illkirch, France.
| | - M Pudlo
- AFECT Association française des Enseignants de Chimie Thérapeutique (French Association of Medicinal Chemistry Teachers), Paris, France; PEPITE EA4267, University Bourgogne Franche-Comté, 19, rue Ambroise Paré, 25000 Besançon, France.
| |
Collapse
|
11
|
Besson T, Fruit C. Recent Advances in Transition-Metal-Free Late-Stage C-H and N-H Arylation of Heteroarenes Using Diaryliodonium Salts. Pharmaceuticals (Basel) 2021; 14:661. [PMID: 34358087 PMCID: PMC8308686 DOI: 10.3390/ph14070661] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Revised: 07/07/2021] [Accepted: 07/09/2021] [Indexed: 12/21/2022] Open
Abstract
Transition-metal-free direct arylation of C-H or N-H bonds is one of the key emerging methodologies that is currently attracting tremendous attention. Diaryliodonium salts serve as a stepping stone on the way to alternative environmentally friendly and straightforward pathways for the construction of C-C and C-heteroatom bonds. In this review, we emphasize the recent synthetic advances of late-stage C(sp2)-N and C(sp2)-C(sp2) bond-forming reactions under metal-free conditions using diaryliodonium salts as arylating reagent and its applications to the synthesis of new arylated bioactive heterocyclic compounds.
Collapse
Affiliation(s)
| | - Corinne Fruit
- Normandie University, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, F-76000 Rouen, France;
| |
Collapse
|
12
|
Elie J, Fruit C, Besson T. Microwave-Assisted Sequential One-Pot Synthesis of 8-Substituted Pyrazolo[1,5- a][1,3,5]triazines. Molecules 2021; 26:molecules26123540. [PMID: 34200623 PMCID: PMC8230123 DOI: 10.3390/molecules26123540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Revised: 06/02/2021] [Accepted: 06/09/2021] [Indexed: 11/16/2022] Open
Abstract
This paper reports a convenient sequential one-pot approach for the synthesis of an array of 14 pyrazolo[1,5-a][1,3,5]triazines, substituted in C8 by halogen (Br), various functions (CN and CO2Et) and alkyl or (het)aryl groups. This study confirms the interest of combining the efficient heating obtained under dielectric microwave heating and the achievement of sequential one-pot reactions, avoiding the tedious work-up and purification of intermediate compounds, achieving sustainable synthesis processes. Considering usual conventional methods, this microwave protocol is featured by advantages in terms of yields, reaction times, and convenient gram scale synthesis.
Collapse
Affiliation(s)
- Jonathan Elie
- Perha Pharmaceuticals, Perharidy Peninsula, 29680 Roscoff, France; (J.E.); (C.F.)
- Normandie University, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France
| | - Corinne Fruit
- Perha Pharmaceuticals, Perharidy Peninsula, 29680 Roscoff, France; (J.E.); (C.F.)
| | - Thierry Besson
- Perha Pharmaceuticals, Perharidy Peninsula, 29680 Roscoff, France; (J.E.); (C.F.)
- Correspondence: ; Tel.: +33-235-522-904
| |
Collapse
|
13
|
Sabater Pastor F, Varesco G, Besson T, Koral J, Feasson L, Millet GY. Degradation of energy cost with fatigue induced by trail running: effect of distance. Eur J Appl Physiol 2021; 121:1665-1675. [PMID: 33666727 DOI: 10.1007/s00421-021-04624-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Accepted: 02/05/2021] [Indexed: 11/29/2022]
Abstract
PURPOSE The effect of trail running competitions on cost of running (Cr) remains unclear and no study has directly examined the effect of distances in similar conditions on Cr. Accordingly, the aims of this study were to (i) assess the effect of trail running races of 40-170 km on Cr and (ii) to assess whether the incline at which Cr is measured influences changes in Cr. METHODS Twenty trail runners completed races of < 100 km (SHORT) and 26 trail runners completed races of > 100 km (LONG) on similar courses and environmental conditions. Oxygen uptake, respiratory exchange ratio, ventilation, and blood lactate were measured before and after the events on a treadmill with 0% (FLAT) and 15% incline (UH) and Cr was calculated. RESULTS Cr increased significantly after SHORT but not LONG races. There was no clear relationship between changes in Cr and changes in ventilation or blood lactate. There was a significant correlation (r = 0.75, p < 0.01) between changes in FLAT and UH Cr, and the change in Cr was not affected by the incline at which Cr was measured. CONCLUSION The distance of the trail running race, but not the slope at which it is measured, influence the changes in Cr with fatigue. The mechanism by which Cr increases only in SHORT is not related to increased cost of breathing.
Collapse
Affiliation(s)
- Frederic Sabater Pastor
- Laboratory of Human Movement Biology (LIBM), Jean Monnet University Saint-Etienne, Campus Santé Innovations, 10 rue de la Marandière, 42270, Saint-Priest en Jarez, France
| | - G Varesco
- Laboratory of Human Movement Biology (LIBM), Jean Monnet University Saint-Etienne, Campus Santé Innovations, 10 rue de la Marandière, 42270, Saint-Priest en Jarez, France
| | - T Besson
- Laboratory of Human Movement Biology (LIBM), Jean Monnet University Saint-Etienne, Campus Santé Innovations, 10 rue de la Marandière, 42270, Saint-Priest en Jarez, France
| | - J Koral
- Laboratory of Human Movement Biology (LIBM), Jean Monnet University Saint-Etienne, Campus Santé Innovations, 10 rue de la Marandière, 42270, Saint-Priest en Jarez, France
| | - L Feasson
- Laboratory of Human Movement Biology (LIBM), Jean Monnet University Saint-Etienne, Campus Santé Innovations, 10 rue de la Marandière, 42270, Saint-Priest en Jarez, France
| | - G Y Millet
- Laboratory of Human Movement Biology (LIBM), Jean Monnet University Saint-Etienne, Campus Santé Innovations, 10 rue de la Marandière, 42270, Saint-Priest en Jarez, France. .,Institut Universitaire de France (IUF), Paris, France.
| |
Collapse
|
14
|
Campos JF, Cailler M, Claudel R, Prot B, Besson T, Berteina-Raboin S. Demonstration of Green Solvent Performance on O,S,N-Heterocycles Synthesis: Metal-Free Click Chemistry and Buchwald-Hartwig Coupling. Molecules 2021; 26:molecules26041074. [PMID: 33670633 PMCID: PMC7922032 DOI: 10.3390/molecules26041074] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 02/15/2021] [Accepted: 02/16/2021] [Indexed: 11/16/2022] Open
Abstract
The development of new and greener approaches to organic synthesis has been a trend in recent years. Continuing the latest publications of our team, in this work, we demonstrate the efficiency of three solvents: eucalyptol (1,8-cineole), cyclopentyl methyl ether (CPME), and 2-methyltetrahydrofuran (2-MeTHF) for the synthesis of O,S,N-heterocyclic compounds.
Collapse
Affiliation(s)
- Joana F. Campos
- Institut de Chimie Organique et Analytique (ICOA), Université d’Orléans UMR-CNRS 7311, BP 6759, Rue de Chartres, 45067 Orléans CEDEX 2, France; (J.F.C.); (M.C.); (R.C.); (B.P.)
| | - Manon Cailler
- Institut de Chimie Organique et Analytique (ICOA), Université d’Orléans UMR-CNRS 7311, BP 6759, Rue de Chartres, 45067 Orléans CEDEX 2, France; (J.F.C.); (M.C.); (R.C.); (B.P.)
| | - Remi Claudel
- Institut de Chimie Organique et Analytique (ICOA), Université d’Orléans UMR-CNRS 7311, BP 6759, Rue de Chartres, 45067 Orléans CEDEX 2, France; (J.F.C.); (M.C.); (R.C.); (B.P.)
| | - Benjamin Prot
- Institut de Chimie Organique et Analytique (ICOA), Université d’Orléans UMR-CNRS 7311, BP 6759, Rue de Chartres, 45067 Orléans CEDEX 2, France; (J.F.C.); (M.C.); (R.C.); (B.P.)
| | - Thierry Besson
- Normandie Univ., UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France;
| | - Sabine Berteina-Raboin
- Institut de Chimie Organique et Analytique (ICOA), Université d’Orléans UMR-CNRS 7311, BP 6759, Rue de Chartres, 45067 Orléans CEDEX 2, France; (J.F.C.); (M.C.); (R.C.); (B.P.)
- Correspondence: ; Tel.: +33-238-494-856
| |
Collapse
|
15
|
Bhansali RS, Rammohan M, Lee P, Laurent AP, Wen Q, Suraneni P, Yip BH, Tsai YC, Jenni S, Bornhauser B, Siret A, Fruit C, Pacheco-Benichou A, Harris E, Besson T, Thompson BJ, Goo YA, Hijiya N, Vilenchik M, Izraeli S, Bourquin JP, Malinge S, Crispino JD. DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3. J Clin Invest 2021; 131:135937. [PMID: 33393494 PMCID: PMC7773384 DOI: 10.1172/jci135937] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Accepted: 08/11/2020] [Indexed: 01/17/2023] Open
Abstract
DYRK1A is a serine/threonine kinase encoded on human chromosome 21 (HSA21) that has been implicated in several pathologies of Down syndrome (DS), including cognitive deficits and Alzheimer's disease. Although children with DS are predisposed to developing leukemia, especially B cell acute lymphoblastic leukemia (B-ALL), the HSA21 genes that contribute to malignancies remain largely undefined. Here, we report that DYRK1A is overexpressed and required for B-ALL. Genetic and pharmacologic inhibition of DYRK1A decreased leukemic cell expansion and suppressed B-ALL development in vitro and in vivo. Furthermore, we found that FOXO1 and STAT3, transcription factors that are indispensable for B cell development, are critical substrates of DYRK1A. Loss of DYRK1A-mediated FOXO1 and STAT3 signaling disrupted DNA damage and ROS regulation, respectively, leading to preferential cell death in leukemic B cells. Thus, we reveal a DYRK1A/FOXO1/STAT3 axis that facilitates the development and maintenance of B-ALL.
Collapse
Affiliation(s)
- Rahul S. Bhansali
- Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, Illinois, USA
| | - Malini Rammohan
- Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, Illinois, USA
| | - Paul Lee
- Abbvie, North Chicago, Illinois, USA
| | | | - Qiang Wen
- Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, Illinois, USA
| | - Praveen Suraneni
- Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, Illinois, USA
| | - Bon Ham Yip
- Division of Experimental Hematology, Department of Hematology, St. Jude Children’s Hospital, Memphis, Tennessee, USA
| | - Yi-Chien Tsai
- Department of Pediatric Oncology, Children’s Research Centre, University Children’s Hospital Zurich, Zurich, Switzerland
| | - Silvia Jenni
- Department of Pediatric Oncology, Children’s Research Centre, University Children’s Hospital Zurich, Zurich, Switzerland
| | - Beat Bornhauser
- Department of Pediatric Oncology, Children’s Research Centre, University Children’s Hospital Zurich, Zurich, Switzerland
| | - Aurélie Siret
- INSERM U1170, Gustave Roussy Institute, Villejuif, France
| | - Corinne Fruit
- Normandie University, UNIROUEN, Institut National des Sciences Appliquées (INSA) Rouen, CNRS, Chimie Organique et Bioorganique — Réactivité et Analyse (COBRA) UMR 6014, Rouen, France
| | - Alexandra Pacheco-Benichou
- Normandie University, UNIROUEN, Institut National des Sciences Appliquées (INSA) Rouen, CNRS, Chimie Organique et Bioorganique — Réactivité et Analyse (COBRA) UMR 6014, Rouen, France
| | - Ethan Harris
- College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Thierry Besson
- Normandie University, UNIROUEN, Institut National des Sciences Appliquées (INSA) Rouen, CNRS, Chimie Organique et Bioorganique — Réactivité et Analyse (COBRA) UMR 6014, Rouen, France
| | | | - Young Ah Goo
- Proteomics Center of Excellence, Northwestern University, Evanston, Illinois, USA
| | - Nobuko Hijiya
- Division of Pediatric Hematology/Oncology, Columbia University, New York, New York, USA
| | | | - Shai Izraeli
- Pediatric Hematology Oncology, Schneider Children’s Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel
| | - Jean-Pierre Bourquin
- Department of Pediatric Oncology, Children’s Research Centre, University Children’s Hospital Zurich, Zurich, Switzerland
| | - Sébastien Malinge
- INSERM U1170, Gustave Roussy Institute, Villejuif, France
- Telethon Kids Institute, Telethon Kids Cancer Centre (TKCC), Nedlands, Western Australia, Australia
| | - John D. Crispino
- Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, Illinois, USA
- Division of Experimental Hematology, Department of Hematology, St. Jude Children’s Hospital, Memphis, Tennessee, USA
| |
Collapse
|
16
|
Blanc D, Racine V, Khalil A, Deloche M, Broyelle JA, Hammouamri I, Sinitambirivoutin E, Fiammante M, Verdier E, Besson T, Sadate A, Lederlin M, Laurent F, Chassagnon G, Ferretti G, Diascorn Y, Brillet PY, Cassagnes L, Caramella C, Loubet A, Abassebay N, Cuingnet P, Ohana M, Behr J, Ginzac A, Veyssiere H, Durando X, Bousaïd I, Lassau N, Brehant J. Artificial intelligence solution to classify pulmonary nodules on CT. Diagn Interv Imaging 2020; 101:803-810. [PMID: 33168496 DOI: 10.1016/j.diii.2020.10.004] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Revised: 10/12/2020] [Accepted: 10/13/2020] [Indexed: 12/20/2022]
Abstract
PURPOSE The purpose of this study was to create an algorithm to detect and classify pulmonary nodules in two categories based on their volume greater than 100 mm3 or not, using machine learning and deep learning techniques. MATERIALS AND METHOD The dataset used to train the model was provided by the organization team of the SFR (French Radiological Society) Data Challenge 2019. An asynchronous and parallel 3-stages pipeline was developed to process all the data (a data "pre-processing" stage; a "nodule detection" stage; a "classifier" stage). Lung segmentation was achieved using 3D U-NET algorithm; nodule detection was done using 3D Retina-UNET and classifier stage with a support vector machine algorithm on selected features. Performances were assessed using area under receiver operating characteristics curve (AUROC). RESULTS The pipeline showed good performance for pathological nodule detection and patient diagnosis. With the preparation dataset, an AUROC of 0.9058 (95% confidence interval [CI]: 0.8746-0.9362) was obtained, 87% yielding accuracy (95% CI: 84.83%-91.03%) for the "nodule detection" stage, corresponding to 86% specificity (95% CI: 82%-92%) and 89% sensitivity (95% CI: 84.83%-91.03%). CONCLUSION A fully functional pipeline using 3D U-NET, 3D Retina-UNET and classifier stage with a support vector machine algorithm was developed, resulting in high capabilities for pulmonary nodule classification.
Collapse
Affiliation(s)
- D Blanc
- QuantaCell, IRMB, Hôpital Saint-Eloi, 34090 Montpellier, France
| | - V Racine
- QuantaCell, IRMB, Hôpital Saint-Eloi, 34090 Montpellier, France
| | - A Khalil
- Department of Radiology, Neuroradiology unit, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat Claude Bernard, 75018 Paris, France; Université de Paris, 75010, Paris, France
| | - M Deloche
- >IBM Cognitive Systems Lab, 34000 Montpellier, France
| | - J-A Broyelle
- >IBM Cognitive Systems Lab, 34000 Montpellier, France
| | - I Hammouamri
- >IBM Cognitive Systems Lab, 34000 Montpellier, France
| | | | - M Fiammante
- IBM Cognitive Systems France, 92270 Bois-Colombes, France
| | - E Verdier
- IBM Cognitive Systems France, 92270 Bois-Colombes, France
| | - T Besson
- IBM Cognitive Systems France, 92270 Bois-Colombes, France
| | - A Sadate
- Department of Radiology and Medical Imaging, CHU Nîmes, University Montpellier, EA2415, 30029 Nîmes, France
| | - M Lederlin
- Department of Radiology, Hôpital Universitaire Pontchaillou, 35000 Rennes, France
| | - F Laurent
- Department of thoracic and cardiovascular Imaging, Respiratory Diseases Service, Respiratory Functional Exploration Service, Hôpital universitaire de Bordeaux, CIC 1401, 33600 Pessac, France
| | - G Chassagnon
- Department of Radiology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 75014, Paris, France & Université de Paris, 75006 Paris, France
| | - G Ferretti
- Department of Radiology and Medical Imaging, CHU Grenoble Alpes, 38700 Grenoble, France
| | - Y Diascorn
- Department of Radiology, Hôpital Universitaire Pasteur, Nice, France
| | - P-Y Brillet
- Inserm UMR 1272, Université Sorbonne Paris Nord, Assistance Publique-Hôpitaux de Paris, Department of Radiology, Hôpital Avicenne, 93430 Bobigny, France
| | - Lucie Cassagnes
- Department of radiology B, CHU Gabriel Montpied, 63003 Clermont-Ferrand, France
| | - C Caramella
- Department of Radiology, Institut Gustave Roussy, 94800 Villejuif, France
| | - A Loubet
- Department of Neuroradiology, Hôpital Gui-de-Chauliac, CHRU de Montpellier, 34000 Montpellier, France
| | - N Abassebay
- Department of Radiology, CH Douai, 59507 Douai, France
| | - P Cuingnet
- Department of Radiology, CH Douai, 59507 Douai, France
| | - M Ohana
- Department of Radiology, Nouvel Hôpital Civil, 67000 Strasbourg, France
| | - J Behr
- Department of Radiology, CHRU de Jean-Minjoz Besançon, 25030 Besançon, France
| | - A Ginzac
- Clinical Research Unit, Clinical Research and Innovation Delegation, Centre de Lutte contre le Cancer, Centre Jean Perrin, 63011 Clermont-Ferrand Cedex 1, France; Université Clermont Auvergne,INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Centre Jean Perrin, 63011 Clermont-Ferrand, France; Clinical Investigation Center, UMR501, 63011 Clermont-Ferrand, France
| | - H Veyssiere
- Clinical Research Unit, Clinical Research and Innovation Delegation, Centre de Lutte contre le Cancer, Centre Jean Perrin, 63011 Clermont-Ferrand Cedex 1, France; Université Clermont Auvergne,INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Centre Jean Perrin, 63011 Clermont-Ferrand, France; Clinical Investigation Center, UMR501, 63011 Clermont-Ferrand, France
| | - X Durando
- Clinical Research Unit, Clinical Research and Innovation Delegation, Centre de Lutte contre le Cancer, Centre Jean Perrin, 63011 Clermont-Ferrand Cedex 1, France; Université Clermont Auvergne,INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Centre Jean Perrin, 63011 Clermont-Ferrand, France; Clinical Investigation Center, UMR501, 63011 Clermont-Ferrand, France; Department of Medical Oncology, Centre Jean Perrin, 63011 Clermont-Ferrand, France
| | - I Bousaïd
- Digital Transformation and Information Systems Division, Gustave Roussy, 94800 Villejuif, France
| | - N Lassau
- Multimodal Biomedical Imaging Laboratory Paris-Saclay, BIOMAPS, UMR 1281, Université Paris-Saclay, Inserm, CNRS, CEA, Department of Radiology, Institut Gustave Roussy, 94800, Villejuif, France
| | - J Brehant
- Department of Radiology, Centre Jean Perrin, 63011 Clermont-Ferrand, France.
| |
Collapse
|
17
|
Rossi J, Besson T, Poncet D, Millet GY, Morio CY.M. Intra- and inter- session reliability of a new method for evaluating toes flexor strength: preliminary study. Comput Methods Biomech Biomed Engin 2020. [DOI: 10.1080/10255842.2020.1815314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- J. Rossi
- Inter-University Laboratory of Human Movement Biology, University of Lyon, UJM-Saint-Etienne, Saint-Etienne, France
| | - T. Besson
- Inter-University Laboratory of Human Movement Biology, University of Lyon, UJM-Saint-Etienne, Saint-Etienne, France
| | - D. Poncet
- Inter-University Laboratory of Human Movement Biology, University of Lyon, UJM-Saint-Etienne, Saint-Etienne, France
| | - G. Y. Millet
- Inter-University Laboratory of Human Movement Biology, University of Lyon, UJM-Saint-Etienne, Saint-Etienne, France
| | - C. Y .M. Morio
- Movement Sciences Department, Decathlon SportsLab, Villeneuve d’Ascq, France
| |
Collapse
|
18
|
Loidreau Y, Nourrisson MR, Fruit C, Corbière C, Marchand P, Besson T. Microwave-Assisted Synthesis of Potential Bioactive Benzo-, Pyrido- or Pyrazino-thieno[3,2- d]pyrimidin-4-amine Analogs of MPC-6827. Pharmaceuticals (Basel) 2020; 13:ph13090202. [PMID: 32825171 PMCID: PMC7558077 DOI: 10.3390/ph13090202] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2020] [Revised: 08/13/2020] [Accepted: 08/17/2020] [Indexed: 11/16/2022] Open
Abstract
Efficient microwave-assisted chemical processes were applied to the synthesis of an array of novel N-(4-methoxyphenylamino)-2-methyl benzo-, pyrido- or pyrazino-thieno[3,2-d]pyrimidin-4-amine derivatives. These heteroaromatic systems were envisioned as potent bioisosteric analogues of MPC-6827, an anticancer agent previously developed until phase II clinical studies. A brief evaluation and comparison of their antiproliferative activity on HT-29 and Caco-2, two human colorectal cancer cell lines, were also reported. At the tested concentrations (5 and 10 µM), thieno[3,2-d]pyrimidin-4-amines 4a and 4c exhibited an inhibitory effect similar to MPC-6827 on human colorectal cancer cell proliferation.
Collapse
Affiliation(s)
- Yvonnick Loidreau
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France; (Y.L.); (C.F.)
| | - Marie-Renée Nourrisson
- Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000 Nantes, France;
| | - Corinne Fruit
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France; (Y.L.); (C.F.)
| | | | - Pascal Marchand
- Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000 Nantes, France;
- Correspondence: (P.M.); (T.B.); Tel.: +33-253-009-155 (P.M.); +33-235-522-904 (T.B.)
| | - Thierry Besson
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France; (Y.L.); (C.F.)
- Correspondence: (P.M.); (T.B.); Tel.: +33-253-009-155 (P.M.); +33-235-522-904 (T.B.)
| |
Collapse
|
19
|
Berteina-Raboin S, Campos JF, Pacheco-Benichou A, Fruit C, Besson T. Synthesis of Benzo-Fused 11H-Pyrido[2,1-b]quinazolin-11-ones by a Buchwald–Hartwig Coupling/Pyridine Dearomatization Sequence in Eucalyptol. SYNTHESIS-STUTTGART 2020. [DOI: 10.1055/s-0040-1707158] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
The synthesis of a new library of polyheterocyclic 11H-pyrido[2,1-b]quinazolin-11-one derivatives was investigated. Satisfactory conditions were obtained via sequential C–N Buchwald–Hartwig coupling and pyridine dearomatization. In this work, traditional solvents were replaced by the bio-sourced eucalyptol, confirming the interest in it as a green solvent in chemistry.
Collapse
Affiliation(s)
| | - Joana F. Campos
- Institut de Chimie Organique et Analytique (ICOA), Université d’Orléans UMR-CNRS 7311
| | | | - Corinne Fruit
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014
| | - Thierry Besson
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014
| |
Collapse
|
20
|
Loidreau Y, Dubouilh-Benard C, Nourrisson MR, Loaëc N, Meijer L, Besson T, Marchand P. Exploring Kinase Inhibition Properties of 9 H-pyrimido[5,4- b]- and [4,5- b]indol-4-amine Derivatives. Pharmaceuticals (Basel) 2020; 13:ph13050089. [PMID: 32397570 PMCID: PMC7281298 DOI: 10.3390/ph13050089] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Revised: 05/01/2020] [Accepted: 05/08/2020] [Indexed: 11/30/2022] Open
Abstract
We previously highlighted the interest in 6,5,6-fused tricyclic analogues of 4-aminoquinazolines as kinase inhibitors in the micromolar to the nanomolar range of IC50 values. For the generation of chemical libraries, the formamide-mediated cyclization of the cyanoamidine precursors was carried out under microwave irradiation in an eco-friendly approach. In order to explore more in-depth the pharmacological interest in such tricyclic skeletons, the central five member ring, i.e., thiophène or furan, was replaced by a pyrrole to afford 9H-pyrimido[5,4-b]- and [4,5-b]indol-4-amine derivatives inspired from harmine. The inhibitory potency of the final products was determined against four protein kinases (CDK5/p25, CK1δ/ε, GSK3α/β, and DYRK1A). As a result, we have identified promising compounds targeting CK1δ/ε and DYRK1A and displaying micromolar and submicromolar IC50 values.
Collapse
Affiliation(s)
- Yvonnick Loidreau
- Normandie Université, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, F-76000 Rouen, France; (Y.L.); (C.D.-B.)
| | - Carole Dubouilh-Benard
- Normandie Université, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, F-76000 Rouen, France; (Y.L.); (C.D.-B.)
| | - Marie-Renée Nourrisson
- Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000 Nantes, France;
| | - Nadège Loaëc
- Station Biologique de Roscoff, Protein Phosphorylation & Human Disease Group, 29680 Roscoff, France; (N.L.); (L.M.)
| | - Laurent Meijer
- Station Biologique de Roscoff, Protein Phosphorylation & Human Disease Group, 29680 Roscoff, France; (N.L.); (L.M.)
- Perha Pharmaceuticals, Perharidy Peninsula, 29680 Roscoff, France
| | - Thierry Besson
- Normandie Université, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, F-76000 Rouen, France; (Y.L.); (C.D.-B.)
- Correspondence: (T.B.); (P.M.); Tel.: +33-235-522-904 (T.B.); +33-253-009-155 (P.M.)
| | - Pascal Marchand
- Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000 Nantes, France;
- Correspondence: (T.B.); (P.M.); Tel.: +33-235-522-904 (T.B.); +33-253-009-155 (P.M.)
| |
Collapse
|
21
|
Fruit C, Couly F, Bhansali R, Rammohan M, Lindberg MF, Crispino JD, Meijer L, Besson T. Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4- f]quinazolin-9(8 H)-one, a Promising Inhibitor of DYRK1A. Pharmaceuticals (Basel) 2019; 12:ph12040185. [PMID: 31861110 PMCID: PMC6958357 DOI: 10.3390/ph12040185] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Revised: 12/13/2019] [Accepted: 12/14/2019] [Indexed: 12/27/2022] Open
Abstract
Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) hyperactivity has been linked to the development of a number of human malignancies. DYRK1A is the most studied family member, and the discovery of novel specific inhibitors is attracting considerable interest. The 8-cyclopropyl-2(pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8H)-one (also called FC162) was found to be a promising inhibitor of DYRK1A and was characterized in biological experiments, by western transfer and flow cytometry on SH-SY5Y and pre-B cells. Here, the results obtained with FC162 are compared to well-characterized known DYRK1A inhibitors (e.g., Leucettine L41 and EHT1610).
Collapse
Affiliation(s)
- Corinne Fruit
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France; (C.F.); (F.C.)
| | - Florence Couly
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France; (C.F.); (F.C.)
| | - Rahul Bhansali
- Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, IL 60611, USA; (R.B.); (M.R.); (J.D.C.)
- College of Medicine, University of Illinois, Chicago, IL 60611, USA
| | - Malini Rammohan
- Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, IL 60611, USA; (R.B.); (M.R.); (J.D.C.)
| | - Mattias F. Lindberg
- ManRos Therapeutics & Perha Pharmaceuticals, Perharidy Peninsula, 29680 Roscoff, France; (M.F.L.); (L.M.)
| | - John D. Crispino
- Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, IL 60611, USA; (R.B.); (M.R.); (J.D.C.)
- Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Laurent Meijer
- ManRos Therapeutics & Perha Pharmaceuticals, Perharidy Peninsula, 29680 Roscoff, France; (M.F.L.); (L.M.)
| | - Thierry Besson
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France; (C.F.); (F.C.)
- Correspondence: ; Tel.: +33-(0)-235-522-904
| |
Collapse
|
22
|
Couly F, Harari M, Dubouilh-Benard C, Bailly L, Petit E, Diharce J, Bonnet P, Meijer L, Fruit C, Besson T. Development of Kinase Inhibitors via Metal-Catalyzed C⁻H Arylation of 8-Alkyl-thiazolo[5,4- f]-quinazolin-9-ones Designed by Fragment-Growing Studies. Molecules 2018; 23:E2181. [PMID: 30158487 PMCID: PMC6225322 DOI: 10.3390/molecules23092181] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2018] [Revised: 08/24/2018] [Accepted: 08/27/2018] [Indexed: 12/14/2022] Open
Abstract
Efficient metal catalyzed C⁻H arylation of 8-alkyl-thiazolo[5,4-f]-quinazolin-9-ones was explored for SAR studies. Application of this powerful chemical tool at the last stage of the synthesis of kinase inhibitors allowed the synthesis of arrays of molecules inspired by fragment-growing studies generated by molecular modeling calculations. Among the potentially active compounds designed through this strategy, FC162 (4c) exhibits nanomolar IC50 values against some kinases, and is the best candidate for the development as a DYRK kinase inhibitor.
Collapse
Affiliation(s)
- Florence Couly
- Normandie University, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France.
| | - Marine Harari
- Normandie University, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France.
| | | | - Laetitia Bailly
- Normandie University, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France.
| | - Emilie Petit
- Normandie University, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France.
| | - Julien Diharce
- Institut de Chimie Organique et Analytique (ICOA), Université d'Orléans, UMR CNRS, 7311 BP 6759, 45067 Orléans CEDEX 2, France.
| | - Pascal Bonnet
- Institut de Chimie Organique et Analytique (ICOA), Université d'Orléans, UMR CNRS, 7311 BP 6759, 45067 Orléans CEDEX 2, France.
| | - Laurent Meijer
- ManRos Therapeutics, Perharidy Peninsula, 29680 Roscoff, France.
| | - Corinne Fruit
- Normandie University, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France.
| | - Thierry Besson
- Normandie University, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France.
| |
Collapse
|
23
|
Letribot B, Delatouche R, Rouillard H, Bonnet A, Chérouvrier JR, Domon L, Besson T, Thiéry V. Synthesis of 2-Mercapto-(2-Oxoindolin-3-Ylidene)Acetonitriles from 3-(4-Chloro-5 H-1,2,3-Dithiazol-5-Ylidene)Indolin-2-ones. Molecules 2018; 23:molecules23061390. [PMID: 29890669 PMCID: PMC6100569 DOI: 10.3390/molecules23061390] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Revised: 06/04/2018] [Accepted: 06/06/2018] [Indexed: 12/02/2022] Open
Abstract
Alkylidene oxindoles are important functional moieties and building blocks in pharmaceutical and synthetic chemistry. Our interest in biologically active compounds focused our studies on the synthesis of novel oxindoles, bearing on the exocyclic double bond at the C8, CN, and S groups. Extending the potential applications of Appel’s salt, we developed a new synthetic approach by investigating the reactions of C5-substituted 2-oxindoles with 4,5-dichloro-1,2,3-dithiazolium chloride (Appel’s salt) to give original (Z)-3-(4-chloro-5H-1,2,3-dithiazol-5-ylidene)indolin-2-one derivatives, and new 2-mercapto-(2-oxoindolin-3-ylidene)acetonitriles via a dithiazole ring-opening reaction. The work described in this article represents further applications of Appel’s salt in the conception of novel heterocyclic rings, in an effort to access original bioactive compounds. Fifteen new compounds were prepared and fully characterized.
Collapse
Affiliation(s)
- Boris Letribot
- University of La Rochelle, UMR CNRS 7266 LIENSs, 17000 La Rochelle, France.
| | - Régis Delatouche
- University of La Rochelle, UMR CNRS 7266 LIENSs, 17000 La Rochelle, France.
| | - Hervé Rouillard
- University of La Rochelle, UMR CNRS 7266 LIENSs, 17000 La Rochelle, France.
| | - Antoine Bonnet
- University of La Rochelle, UMR CNRS 7266 LIENSs, 17000 La Rochelle, France.
| | | | - Lisianne Domon
- University of La Rochelle, UMR CNRS 7266 LIENSs, 17000 La Rochelle, France.
| | - Thierry Besson
- Normandie University, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France.
| | - Valérie Thiéry
- University of La Rochelle, UMR CNRS 7266 LIENSs, 17000 La Rochelle, France.
| |
Collapse
|
24
|
Affiliation(s)
- T Besson
- a Inter-university Laboratory of Human Movement Biology (EA 7424 ), University of Lyon, University Jean Monnet , Saint-Etienne , France
| | - C Morio
- b Decathlon SportsLab, Movement Sciences Department , Villeneuve d'Ascq , France
| | - J Rossi
- a Inter-university Laboratory of Human Movement Biology (EA 7424 ), University of Lyon, University Jean Monnet , Saint-Etienne , France
| |
Collapse
|
25
|
Nguyen TL, Fruit C, Hérault Y, Meijer L, Besson T. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature. Expert Opin Ther Pat 2017; 27:1183-1199. [PMID: 28766366 DOI: 10.1080/13543776.2017.1360285] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
INTRODUCTION Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a eukaryotic serine-threonine protein kinase belonging to the CMGC group. DYRK1A hyperactivity appears to contribute to the development of a number of human malignancies and to cognitive deficits observed in Down syndrome and Alzheimer's disease. As a result, the DYRK1A kinase represents an attractive target for the synthesis and optimization of pharmacological inhibitors of potential therapeutic interest. Like most tyrosine kinase inhibitors developed up to the market, DYRK1A inhibitors are essentially acting by competing with ATP for binding at the catalytic site of the kinase. Areas covered: This paper reviews patent activity associated with the discovery of synthetic novel heterocyclic molecules inhibiting the catalytic activity of DYRK1A. Expert opinion: Despite the important role of DYRK1A in biological processes and the growing interest in the design of new therapeutic drugs, there are only few patented synthetic DYRK1A inhibitors and most of them were and are still developed by academic research groups, sometimes with industrial partners.
Collapse
Affiliation(s)
- Thu Lan Nguyen
- a Manros Therapeutics , Centre de Perharidy , Roscoff , France
- b Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch , Illkirch , France
- c Centre National de la Recherche Scientifique, UMR7104 , Illkirch , France
- d Institut National de la Santé et de la Recherche Médicale, U964 , Illkirch , France
- e Université de Strasbourg , Illkirch , France
| | - Corinne Fruit
- f Normandie Univ , UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014 , Rouen , France
| | - Yann Hérault
- a Manros Therapeutics , Centre de Perharidy , Roscoff , France
- b Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch , Illkirch , France
- c Centre National de la Recherche Scientifique, UMR7104 , Illkirch , France
- d Institut National de la Santé et de la Recherche Médicale, U964 , Illkirch , France
- e Université de Strasbourg , Illkirch , France
| | - Laurent Meijer
- a Manros Therapeutics , Centre de Perharidy , Roscoff , France
| | - Thierry Besson
- f Normandie Univ , UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014 , Rouen , France
| |
Collapse
|
26
|
Couly F, Dubouilh-Benard C, Besson T, Fruit C. Late-Stage C–H Arylation of Thiazolo[5,4-f]quinazolin-9(8H)-one Backbone: Synthesis of an Array of Potential Kinase Inhibitors. SYNTHESIS-STUTTGART 2017. [DOI: 10.1055/s-0036-1588434] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Driven by the need of structural modification to establish structure-activity relationships, the regioselective C–H bond activation of thiazolo[5,4-f]quinazolin-9(8H)-one backbone has been developed to furnish the corresponding C2-arylated valuable scaffold. This strategy provides a synthetically streamlined and useful route for late-stage diversification of this attractive skeleton, required in drug discovery. A more eco-friendly synthesis of thiazolo[5,4-f]quinazolin-9(8H)-ones is also described giving access to these aforementioned compounds in a facile manner.
Collapse
Affiliation(s)
- Florence Couly
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014
| | | | - Thierry Besson
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014
| | - Corinne Fruit
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014
| |
Collapse
|
27
|
Chaikuad A, Diharce J, Schröder M, Foucourt A, Leblond B, Casagrande AS, Désiré L, Bonnet P, Knapp S, Besson T. An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases. J Med Chem 2016; 59:10315-10321. [DOI: 10.1021/acs.jmedchem.6b01083] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Apirat Chaikuad
- Target
Discovery Institute (TDI), and Structural Genomics Consortium (SGC), University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, U.K
| | - Julien Diharce
- Institut
de Chimie Organique et Analytique, UMR CNRS-Université d’Orléans
7311, Université d’Orléans, BP 6759, Orléans 45067 Cedex 2, France
| | - Martin Schröder
- Institute
of Pharmaceutical Chemistry and Buchman Institute for Life Sciences, Goethe-University, Max-von-Laue-Strasse 9, 60438 Frankfurt am Main, Germany
| | - Alicia Foucourt
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France
| | | | | | | | - Pascal Bonnet
- Institut
de Chimie Organique et Analytique, UMR CNRS-Université d’Orléans
7311, Université d’Orléans, BP 6759, Orléans 45067 Cedex 2, France
| | - Stefan Knapp
- Target
Discovery Institute (TDI), and Structural Genomics Consortium (SGC), University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, U.K
- Institute
of Pharmaceutical Chemistry and Buchman Institute for Life Sciences, Goethe-University, Max-von-Laue-Strasse 9, 60438 Frankfurt am Main, Germany
| | - Thierry Besson
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France
| |
Collapse
|
28
|
Fruit C, Besson T. Recent Developments in Microwave-Assisted Metal-Catalyzed C–H Functionalization of Heteroarenes for Medicinal Chemistry and Material Applications. SYNTHESIS-STUTTGART 2016. [DOI: 10.1055/s-0035-1562608] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
29
|
|
30
|
Hédou D, Dubouilh-Benard C, Loaëc N, Meijer L, Fruit C, Besson T. Synthesis of Bioactive 2-(Arylamino)thiazolo[5,4-f]-quinazolin-9-ones via the Hügershoff Reaction or Cu- Catalyzed Intramolecular C-S Bond Formation. Molecules 2016; 21:molecules21060794. [PMID: 27322235 PMCID: PMC6272913 DOI: 10.3390/molecules21060794] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2016] [Revised: 06/12/2016] [Accepted: 06/13/2016] [Indexed: 11/16/2022] Open
Abstract
A library of thirty eight novel thiazolo[5,4-f]quinazolin-9(8H)-one derivatives (series 8, 10, 14 and 17) was prepared via the Hügershoff reaction and a Cu catalyzed intramolecular C-S bond formation, helped by microwave-assisted technology when required. The efficient multistep synthesis of the key 6-amino-3-cyclopropylquinazolin-4(3H)-one (3) has been reinvestigated and performed on a multigram scale from the starting 5-nitroanthranilic acid. The inhibitory potency of the final products was evaluated against five kinases involved in Alzheimer's disease and showed that some molecules of the 17 series described in this paper are particularly promising for the development of novel multi-target inhibitors of kinases.
Collapse
Affiliation(s)
- Damien Hédou
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France.
| | | | - Nadège Loaëc
- Protein Phosphorylation & Human Disease group, Station Biologique, 29680 Roscoff, France.
- Manros Therapeutics, Centre de Perharidy, 29680 Roscoff, France.
| | - Laurent Meijer
- Manros Therapeutics, Centre de Perharidy, 29680 Roscoff, France.
| | - Corinne Fruit
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France.
| | - Thierry Besson
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France.
| |
Collapse
|
31
|
Harari M, Couly F, Fruit C, Besson T. Pd-Catalyzed and Copper Assisted Regioselective Sequential C2 and C7 Arylation of Thiazolo[5,4-f]quinazolin-9(8H)-one with Aryl Halides. Org Lett 2016; 18:3282-5. [PMID: 27314437 DOI: 10.1021/acs.orglett.6b01552] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A selective functionalization of thiazolo[5,4-f]quinazolin-9(8H)-one has been developed through sequential activation of C-H bonds to furnish diarylated compounds. This strategy allows the regioselective C2 and C7 arylation by a judicious choice of coupling partners and bases, requiring no additional ligands or directing groups. Differently substituted N(8)-benzylated-2,7-diaryl-thiazoloquinazolin-9(8H)-ones were thereby obtained in a facile manner. A one-pot procedure was also performed. These protocols provide a synthetically useful route for late-stage functionalization of this highly valuable scaffold, required in drug discovery.
Collapse
Affiliation(s)
- Marine Harari
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France
| | - Florence Couly
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France
| | - Corinne Fruit
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France
| | - Thierry Besson
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France
| |
Collapse
|
32
|
Godeau J, Harari M, Laclef S, Deau E, Fruit C, Besson T. Cu/Pd-Catalyzed C-2-H Arylation of Quinazolin-4(3H)-ones with (Hetero)aryl Halides. European J Org Chem 2015. [DOI: 10.1002/ejoc.201501129] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
33
|
Thompson BJ, Bhansali R, Diebold L, Cook DE, Stolzenburg L, Casagrande AS, Besson T, Leblond B, Désiré L, Malinge S, Crispino JD. DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3. J Biophys Biochem Cytol 2015. [DOI: 10.1083/jcb.2095oia105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
34
|
Thompson BJ, Bhansali R, Diebold L, Cook DE, Stolzenburg L, Casagrande AS, Besson T, Leblond B, Désiré L, Malinge S, Crispino JD. DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3. J Exp Med 2015; 212:953-70. [PMID: 26008897 PMCID: PMC4451127 DOI: 10.1084/jem.20150002] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2015] [Accepted: 04/29/2015] [Indexed: 11/16/2022] Open
Abstract
Pre-B and pre-T lymphocytes must orchestrate a transition from a highly proliferative state to a quiescent one during development. Cyclin D3 is essential for these cells' proliferation, but little is known about its posttranslational regulation at this stage. Here, we show that the dual specificity tyrosine-regulated kinase 1A (DYRK1A) restrains Cyclin D3 protein levels by phosphorylating T283 to induce its degradation. Loss of DYRK1A activity, via genetic inactivation or pharmacologic inhibition in mice, caused accumulation of Cyclin D3 protein, incomplete repression of E2F-mediated gene transcription, and failure to properly couple cell cycle exit with differentiation. Expression of a nonphosphorylatable Cyclin D3 T283A mutant recapitulated these defects, whereas inhibition of Cyclin D:CDK4/6 mitigated the effects of DYRK1A inhibition or loss. These data uncover a previously unknown role for DYRK1A in lymphopoiesis, and demonstrate how Cyclin D3 protein stability is negatively regulated during exit from the proliferative phases of B and T cell development.
Collapse
Affiliation(s)
| | - Rahul Bhansali
- Division of Hematology/Oncology, Northwestern University, Chicago, IL 60208
| | - Lauren Diebold
- Division of Hematology/Oncology, Northwestern University, Chicago, IL 60208
| | - Daniel E Cook
- Division of Hematology/Oncology, Northwestern University, Chicago, IL 60208
| | | | | | - Thierry Besson
- Normandie Université, COBRA, UMR 6014 and FR 3038; Université Rouen; INSA Rouen; Centre National de la Recherche Scientifique, Bâtiment IRCOF, 76821 Mont St. Aignan, France
| | | | | | | | - John D Crispino
- Division of Hematology/Oncology, Northwestern University, Chicago, IL 60208
| |
Collapse
|
35
|
Coutadeur S, Benyamine H, Delalonde L, de Oliveira C, Leblond B, Foucourt A, Besson T, Casagrande AS, Taverne T, Girard A, Pando MP, Désiré L. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro. J Neurochem 2015; 133:440-51. [PMID: 25556849 DOI: 10.1111/jnc.13018] [Citation(s) in RCA: 88] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2014] [Revised: 11/26/2014] [Accepted: 12/07/2014] [Indexed: 12/18/2022]
Abstract
The dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) gene is located within the Down Syndrome (DS) critical region on chromosome 21 and is implicated in the generation of Tau and amyloid pathologies that are associated with the early onset Alzheimer's Disease (AD) observed in DS. DYRK1A is also found associated with neurofibrillary tangles in sporadic AD and phosphorylates key AD players (Tau, amyloid precursor, protein, etc). Thus, DYRK1A may be an important therapeutic target to modify the course of Tau and amyloid beta (Aβ) pathologies. Here, we describe EHT 5372 (methyl 9-(2,4-dichlorophenylamino) thiazolo[5,4-f]quinazoline-2-carbimidate), a novel, highly potent (IC50 = 0.22 nM) DYRK1A inhibitor with a high degree of selectivity over 339 kinases. Models in which inhibition of DYRK1A by siRNA reduced and DYRK1A over-expression induced Tau phosphorylation or Aβ production were used. EHT 5372 inhibits DYRK1A-induced Tau phosphorylation at multiple AD-relevant sites in biochemical and cellular assays. EHT 5372 also normalizes both Aβ-induced Tau phosphorylation and DYRK1A-stimulated Aβ production. DYRK1A is thus as a key element of Aβ-mediated Tau hyperphosphorylation, which links Tau and amyloid pathologies. EHT 5372 and other compounds in its class warrant in vivo investigation as a novel, high-potential therapy for AD and other Tau opathies. Inhibition of the dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is a new high-potential therapeutic approach for Alzheimer disease. Here we describe EHT 5372, a novel potent and selective DYRK1A inhibitor. EHT 5372 inhibits DYRK1A-induced Tau phosphorylation, Aβ production and Aβ effects on phospho-Tau, including Tau aggregation.
Collapse
|
36
|
Laclef S, Harari M, Godeau J, Schmitz-Afonso I, Bischoff L, Hoarau C, Levacher V, Fruit C, Besson T. Ligand-free Pd-catalyzed and copper-assisted C-H arylation of quinazolin-4-ones with aryl iodides under microwave heating. Org Lett 2015; 17:1700-3. [PMID: 25781369 DOI: 10.1021/acs.orglett.5b00467] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
A microwave-assisted method for the palladium-catalyzed direct arylation of quinazolin-4-one has been developed under copper-assistance. This method is applicable to a wide range of aryl iodides and substituted (2H)-quinazolin-4-ones. This protocol provides a simple and efficient way to synthesize biologically relevant 2-arylquinazolin-4-one backbones.
Collapse
Affiliation(s)
- Sylvain Laclef
- Normandie Univ, COBRA, UMR 6014 et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière, 76821 Mont Saint Aignan Cedex, France
| | - Marine Harari
- Normandie Univ, COBRA, UMR 6014 et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière, 76821 Mont Saint Aignan Cedex, France
| | - Julien Godeau
- Normandie Univ, COBRA, UMR 6014 et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière, 76821 Mont Saint Aignan Cedex, France
| | - Isabelle Schmitz-Afonso
- Normandie Univ, COBRA, UMR 6014 et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière, 76821 Mont Saint Aignan Cedex, France
| | - Laurent Bischoff
- Normandie Univ, COBRA, UMR 6014 et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière, 76821 Mont Saint Aignan Cedex, France
| | - Christophe Hoarau
- Normandie Univ, COBRA, UMR 6014 et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière, 76821 Mont Saint Aignan Cedex, France
| | - Vincent Levacher
- Normandie Univ, COBRA, UMR 6014 et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière, 76821 Mont Saint Aignan Cedex, France
| | - Corinne Fruit
- Normandie Univ, COBRA, UMR 6014 et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière, 76821 Mont Saint Aignan Cedex, France
| | - Thierry Besson
- Normandie Univ, COBRA, UMR 6014 et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière, 76821 Mont Saint Aignan Cedex, France
| |
Collapse
|
37
|
Loidreau Y, Deau E, Marchand P, Nourrisson MR, Logé C, Coadou G, Loaëc N, Meijer L, Besson T. Synthesis and molecular modelling studies of 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors. Eur J Med Chem 2014; 92:124-34. [PMID: 25549552 DOI: 10.1016/j.ejmech.2014.12.038] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2014] [Revised: 12/10/2014] [Accepted: 12/21/2014] [Indexed: 02/07/2023]
Abstract
This paper reports the design and synthesis of a novel series of 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines via microwave-assisted multi-step synthesis. A common precursor of the whole series, 3-amino-5-bromothieno[2,3-b]pyridine-2-carbonitrile, was rapidly synthesized in one step from commercially-available 5-bromo-2-chloronicotinonitrile. Formylation with DMF-DMA led to (E)-N'-(5-bromo-2-cyanothieno[2,3-b]pyridin-3-yl)-N,N-dimethylformimidamide (4) which was conveniently functionalized at position 8 by palladium-catalyzed Suzuki-Miyaura cross-coupling to introduce a heteroaromatic ring. High-temperature formamide-mediated cyclization of the cyanoamidine intermediate gave seventeen 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines. The inhibitory potency of the final products was evaluated against five protein kinases (CDK5/p25, CK1δ/ε, GSK3α/β, DYRK1A and CLK1) and revealed that 8-(2,4-dichlorophenyl)pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine 1g specifically inhibits CK1δ/ε and CLK1 (220 and 88 nM, respectively) while its 7-(2,4-dichlorophenyl)pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine isomer 10 showed no activity on the panel of tested kinases. Molecular modelling of 10 and 1g in the ATP binding sites of CK1δ/ε and CLK1 showed that functionalization at position 7 of pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines is likely to induce a steric clash on the CK1δ/ε P-loop and thus a complete loss of inhibitory activity.
Collapse
Affiliation(s)
- Yvonnick Loidreau
- Normandie Univ, COBRA, UMR 6014 & FR 3038; Univ Rouen; INSA Rouen; CNRS, Bâtiment IRCOF, 1 rue Tesnière, 76821 Mont St Aignan Cedex, France
| | - Emmanuel Deau
- Normandie Univ, COBRA, UMR 6014 & FR 3038; Univ Rouen; INSA Rouen; CNRS, Bâtiment IRCOF, 1 rue Tesnière, 76821 Mont St Aignan Cedex, France
| | - Pascal Marchand
- Université de Nantes, Nantes Atlantique Universités, Laboratoire de Chimie Thérapeutique, Cibles et Médicaments des Infections et du Cancer, IICiMed UPRES EA 1155, UFR des Sciences Pharmaceutiques et Biologiques, 1 rue Gaston Veil, 44035 Nantes, France
| | - Marie-Renée Nourrisson
- Université de Nantes, Nantes Atlantique Universités, Laboratoire de Chimie Thérapeutique, Cibles et Médicaments des Infections et du Cancer, IICiMed UPRES EA 1155, UFR des Sciences Pharmaceutiques et Biologiques, 1 rue Gaston Veil, 44035 Nantes, France
| | - Cédric Logé
- Université de Nantes, Nantes Atlantique Universités, Laboratoire de Chimie Thérapeutique, Cibles et Médicaments des Infections et du Cancer, IICiMed UPRES EA 1155, UFR des Sciences Pharmaceutiques et Biologiques, 1 rue Gaston Veil, 44035 Nantes, France
| | - Gaël Coadou
- Normandie Univ, COBRA, UMR 6014 & FR 3038; Univ Rouen; INSA Rouen; CNRS, Bâtiment IRCOF, 1 rue Tesnière, 76821 Mont St Aignan Cedex, France
| | - Nadège Loaëc
- Protein Phosphorylation & Human Disease Group, Station Biologique, 29680 Roscoff, France; Manros Therapeutics, Centre de Perharidy, 29680 Roscoff, France
| | - Laurent Meijer
- Manros Therapeutics, Centre de Perharidy, 29680 Roscoff, France
| | - Thierry Besson
- Normandie Univ, COBRA, UMR 6014 & FR 3038; Univ Rouen; INSA Rouen; CNRS, Bâtiment IRCOF, 1 rue Tesnière, 76821 Mont St Aignan Cedex, France.
| |
Collapse
|
38
|
Foucourt A, Hédou D, Dubouilh-Benard C, Désiré L, Casagrande AS, Leblond B, Loäec N, Meijer L, Besson T. Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I. Molecules 2014; 19:15546-71. [PMID: 25268714 PMCID: PMC6270991 DOI: 10.3390/molecules191015546] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2014] [Revised: 09/19/2014] [Accepted: 09/22/2014] [Indexed: 11/16/2022] Open
Abstract
The convenient synthesis of a library of novel 6,6,5-tricyclic thiazolo[5,4-f] quinazolines (forty molecules) was achieved mainly under microwave irradiation. Dimroth rearrangement and 4,5-dichloro-1,2,3,-dithiazolium chloride (Appel salt) chemistry were associated for the synthesis of a novel 6-aminobenzo[d]thiazole-2,7-dicarbonitrile (16) a versatile molecular platform for the synthesis of various bioactive derivatives. Kinase inhibition of the final compounds was evaluated on a panel of four Ser/Thr kinases (DYRK1A, CDK5, CK1 and GSK3) chosen for their strong implications in various regulation processes, especially Alzheimer's disease (AD). In view of the results of this preliminary screening, thiazolo[5,4-f]quinazoline scaffolds constitutes a promising source of inspiration for the synthesis of novel bioactive molecules. Among the compounds of this novel chemolibrary, 7i, 8i and 9i inhibited DYRK1A with IC50 values ranging in the double-digit nanomolar range (40, 47 and 50 nM, respectively).
Collapse
Affiliation(s)
- Alicia Foucourt
- Normandie Université, Laboratoire C.O.B.R.A., UMR 6014 and FR 3038; Université de Rouen; INSA de Rouen; CNRS, Bâtiment I.R.C.O.F. rue Tesnière, Mont-Saint-Aignan F-76821, France.
| | - Damien Hédou
- Normandie Université, Laboratoire C.O.B.R.A., UMR 6014 and FR 3038; Université de Rouen; INSA de Rouen; CNRS, Bâtiment I.R.C.O.F. rue Tesnière, Mont-Saint-Aignan F-76821, France.
| | - Carole Dubouilh-Benard
- Normandie Université, Laboratoire C.O.B.R.A., UMR 6014 and FR 3038; Université de Rouen; INSA de Rouen; CNRS, Bâtiment I.R.C.O.F. rue Tesnière, Mont-Saint-Aignan F-76821, France.
| | | | | | | | - Nadège Loäec
- Protein Phosphorylation & Human Disease group, CNRS, Station Biologique, Roscoff F-29680, France.
| | - Laurent Meijer
- ManRos Therapeutics, Centre de Perharidy, Roscoff F-29680, France.
| | - Thierry Besson
- Normandie Université, Laboratoire C.O.B.R.A., UMR 6014 and FR 3038; Université de Rouen; INSA de Rouen; CNRS, Bâtiment I.R.C.O.F. rue Tesnière, Mont-Saint-Aignan F-76821, France.
| |
Collapse
|
39
|
Foucourt A, Hédou D, Dubouilh-Benard C, Girard A, Taverne T, Casagrande AS, Désiré L, Leblond B, Besson T. Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II. Molecules 2014; 19:15411-39. [PMID: 25264830 PMCID: PMC6271009 DOI: 10.3390/molecules191015411] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2014] [Revised: 09/15/2014] [Accepted: 09/16/2014] [Indexed: 12/12/2022] Open
Abstract
The convenient synthesis of a focused library (forty molecules) of novel 6,6,5-tricyclic thiazolo[5,4-f]quinazolines was realized mainly under microwave irradiation. A novel 6-aminobenzo[d]thiazole-2,7-dicarbonitrile (1) was used as a versatile molecular platform for the synthesis of various derivatives. Kinase inhibition, of the obtained final compounds, was evaluated on a panel of two kinases (DYRK1A/1B) together with some known reference DYRK1A and DYRK1B inhibitors (harmine, TG003, NCGC-00189310 and leucettine L41). Compound IC50 values were obtained and compared. Five of the novel thiazolo[5,4-f]quinazoline derivatives prepared, EHT 5372 (8c), EHT 6840 (8h), EHT 1610 (8i), EHT 9851 (8k) and EHT 3356 (9b) displayed single-digit nanomolar or subnanomolar IC50 values and are among the most potent DYRK1A/1B inhibitors disclosed to date. DYRK1A/1B kinases are known to be involved in the regulation of various molecular pathways associated with oncology, neurodegenerative diseases (such as Alzheimer disease, AD, or other tauopathies), genetic diseases (such as Down Syndrome, DS), as well as diseases involved in abnormal pre-mRNA splicing. The compounds described in this communication constitute a highly potent set of novel molecular probes to evaluate the biology/pharmacology of DYR1A/1B in such diseases.
Collapse
Affiliation(s)
- Alicia Foucourt
- Normandie Univ, Laboratoire C.O.B.R.A., UMR 6014 and FR 3038; Univ Rouen; INSA de Rouen; CNRS, Bâtiment I.R.C.O.F. rue Tesnière, Mont-Saint-Aignan F-76821, France.
| | - Damien Hédou
- Normandie Univ, Laboratoire C.O.B.R.A., UMR 6014 and FR 3038; Univ Rouen; INSA de Rouen; CNRS, Bâtiment I.R.C.O.F. rue Tesnière, Mont-Saint-Aignan F-76821, France.
| | - Carole Dubouilh-Benard
- Normandie Univ, Laboratoire C.O.B.R.A., UMR 6014 and FR 3038; Univ Rouen; INSA de Rouen; CNRS, Bâtiment I.R.C.O.F. rue Tesnière, Mont-Saint-Aignan F-76821, France.
| | | | | | | | | | | | - Thierry Besson
- Normandie Univ, Laboratoire C.O.B.R.A., UMR 6014 and FR 3038; Univ Rouen; INSA de Rouen; CNRS, Bâtiment I.R.C.O.F. rue Tesnière, Mont-Saint-Aignan F-76821, France.
| |
Collapse
|
40
|
Hédou D, Deau E, Harari M, Sanselme M, Fruit C, Besson T. Rational multistep synthesis of a novel polyfunctionalized benzo[d]thiazole and its thiazolo[5,4-b]pyridine analogue. Tetrahedron 2014. [DOI: 10.1016/j.tet.2014.06.103] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
41
|
Deau E, Loidreau Y, Marchand P, Nourrisson MR, Loaëc N, Meijer L, Levacher V, Besson T. Synthesis of novel 7-substituted pyrido[2',3':4,5]furo[3,2-d]pyrimidin-4-amines and their N-aryl analogues and evaluation of their inhibitory activity against Ser/Thr kinases. Bioorg Med Chem Lett 2013; 23:6784-8. [PMID: 24176400 DOI: 10.1016/j.bmcl.2013.10.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2013] [Revised: 10/07/2013] [Accepted: 10/08/2013] [Indexed: 10/26/2022]
Abstract
The efficient synthesis of 7-substituted pyrido[2',3':4,5]furo[3,2-d]pyrimidin-4-amines and their N-aryl analogues is described. 3,5-Dibromopyridine was converted into 3-amino-6-bromofuro[3,2-b]pyridine-2-carbonitrile intermediate which was formylated with DMFDMA. Functionalization at position 7 of the tricyclic scaffold was accomplished, before or after cyclisation step, by palladium-catalyzed Suzuki-Miyaura cross-coupling while the pyrimidin-4-amines and N-aryl counterparts were synthesized by microwave-assisted formamide degradation and Dimroth rearrangement, respectively. The final products were evaluated for their potent inhibition of a series of five Ser/Thr kinases (CDK5/p25, CK1δ/ε, CLK1, DYRK1A, GSK3α/β). Compound 35 showed the best inhibitory activity with an IC50 value of 49 nM and proved to be specific to CLK1 among the panel of tested kinases.
Collapse
Affiliation(s)
- Emmanuel Deau
- Normandie Univ, COBRA, UMR 6014 & FR 3038; Univ Rouen; INSA Rouen; CNRS, Bâtiment IRCOF, 1 rue Tesnière, 76821 Mont St Aignan Cedex, France
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Hédou D, Deau E, Dubouilh-Benard C, Sanselme M, Martinet A, Chosson E, Levacher V, Besson T. Microwave-Assisted [3+2] Cycloaddition and Suzuki-Miyaura Cross-Coupling for a Concise Access to Polyaromatic Scaffolds. European J Org Chem 2013. [DOI: 10.1002/ejoc.201301014] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
43
|
Postikova S, Sabbah M, Wightman D, Nguyen IT, Sanselme M, Besson T, Brière JF, Oudeyer S, Levacher V. Developments in Meyers’ Lactamization Methodology: En Route to Bi(hetero)aryl Structures with Defined Axial Chirality. J Org Chem 2013; 78:8191-7. [DOI: 10.1021/jo401259w] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Svetlana Postikova
- Normandie Univ, COBRA, UMR 6014
et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière,
76821 Mont Saint Aignan Cedex, France
| | - Mohamad Sabbah
- Normandie Univ, COBRA, UMR 6014
et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière,
76821 Mont Saint Aignan Cedex, France
| | - Daniel Wightman
- Normandie Univ, COBRA, UMR 6014
et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière,
76821 Mont Saint Aignan Cedex, France
| | - Ich Tuan Nguyen
- Normandie Univ, COBRA, UMR 6014
et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière,
76821 Mont Saint Aignan Cedex, France
| | - Morgane Sanselme
- Laboratoire SMS − Unité
de cristallogenèse IRCOF, 1 rue Tesnière, 76821 Mont
Saint Aignan Cedex, France
| | - Thierry Besson
- Normandie Univ, COBRA, UMR 6014
et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière,
76821 Mont Saint Aignan Cedex, France
| | - Jean-François Brière
- Normandie Univ, COBRA, UMR 6014
et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière,
76821 Mont Saint Aignan Cedex, France
| | - Sylvain Oudeyer
- Normandie Univ, COBRA, UMR 6014
et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière,
76821 Mont Saint Aignan Cedex, France
| | - Vincent Levacher
- Normandie Univ, COBRA, UMR 6014
et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, 1 rue Tesnière,
76821 Mont Saint Aignan Cedex, France
| |
Collapse
|
44
|
Loidreau Y, Dubouilh-Benard C, Marchand P, Nourrisson MR, Duflos M, Buquet C, Corbière C, Besson T. Efficient New Synthesis of N-Arylbenzo[ b]furo[3,2- d]pyrimidin-4-amines and Their Benzo[ b]thieno[3,2- d]pyrimidin-4-amine Analogues via a Microwave-Assisted Dimroth Rearrangement. J Heterocycl Chem 2013. [DOI: 10.1002/jhet.1716] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Yvonnick Loidreau
- Université de Rouen, CNRS UMR 6014 - C.O.B.R.A. & FR3038, Equipe Hétérocycles; Institut de Recherche en Chimie Organique Fine (I.R.C.O.F.); rue Tesnière; 76130; Mont Saint-Aignan; France
| | - Carole Dubouilh-Benard
- Université de Rouen, CNRS UMR 6014 - C.O.B.R.A. & FR3038, Equipe Hétérocycles; Institut de Recherche en Chimie Organique Fine (I.R.C.O.F.); rue Tesnière; 76130; Mont Saint-Aignan; France
| | - Pascal Marchand
- Université de Nantes, Nantes Atlantique Universités; Laboratoire de Chimie Thérapeutique, Cibles et Médicaments des Infections, de l'Immunité et du Cancer, IICiMed UPRES EA 1155, UFR de Sciences Pharmaceutiques et Biologiques; 1 rue Gaston Veil; 44035; Nantes; France
| | - Marie-Renée Nourrisson
- Université de Nantes, Nantes Atlantique Universités; Laboratoire de Chimie Thérapeutique, Cibles et Médicaments des Infections, de l'Immunité et du Cancer, IICiMed UPRES EA 1155, UFR de Sciences Pharmaceutiques et Biologiques; 1 rue Gaston Veil; 44035; Nantes; France
| | - Muriel Duflos
- Université de Nantes, Nantes Atlantique Universités; Laboratoire de Chimie Thérapeutique, Cibles et Médicaments des Infections, de l'Immunité et du Cancer, IICiMed UPRES EA 1155, UFR de Sciences Pharmaceutiques et Biologiques; 1 rue Gaston Veil; 44035; Nantes; France
| | - Catherine Buquet
- Université de Rouen; EA 3829, UFR Médecine-Pharmacie; 22 Boulevard Gambetta; 76183; Rouen cedex 1; France
| | - Cécile Corbière
- Université de Rouen; EA 3829, UFR Médecine-Pharmacie; 22 Boulevard Gambetta; 76183; Rouen cedex 1; France
| | - Thierry Besson
- Université de Rouen, CNRS UMR 6014 - C.O.B.R.A. & FR3038, Equipe Hétérocycles; Institut de Recherche en Chimie Organique Fine (I.R.C.O.F.); rue Tesnière; 76130; Mont Saint-Aignan; France
| |
Collapse
|
45
|
Deau E, Hédou D, Chosson E, Levacher V, Besson T. Convenient one-pot synthesis of N3-substituted pyrido[2,3-d]-, pyrido[3,4-d]-, pyrido[4,3-d]-pyrimidin-4(3H)-ones, and quinazolin-4(3H)-ones analogs. Tetrahedron Lett 2013. [DOI: 10.1016/j.tetlet.2013.04.096] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
46
|
Deng X, Hu J, Cunningham M, Leblond B, Besson T, Casagrande AS, Désiré L, Friedman EA. Abstract 2164: Mirk/dyrk1B kinase inhibitor reduces the viability of patient-derived ovarian cancer ascites cells and the size of murine tumor xenografts. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-2164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Ovarian cancer is one of the most deadly malignancies for women because it typically presents at a late stage when conventional therapies have limited effect. Ovarian cancer often metastasizes by forming peritoneal ascites, consisting of tumor spheroids within a large fluid volume. Others have shown that ascites tumor spheroids are largely quiescent with about 85% in G0/G1, but retain the capacity to re-enter the cell cycle after attachment to the peritoneal cavity walls. Mirk/dyrk1B kinase is most highly expressed when cancer cells are quiescent, and is known to maintain cells in quiescence by destabilizing cyclin D isoforms and by phosphorylating a member of the DREAM complex that enables p130/Rb2 to sequester transcription factors. In earlier studies, Mirk/dyrk1B kinase inhibition or depletion in quiescent adherent cancer cells, either ovarian or pancreatic, allowed cells to escape quiescence, enter cycle prematurely and suffer DNA damage and subsequent apoptosis. No such effects were seen in normal diploid cells in which Mirk/dyrk1B kinase was in low abundance and had low activity, and diploid cells have a normal complement of CDK inhibitors to prevent escape from quiescence. We now show that spheroids from three ovarian cancer cell lines and the Panc1 pancreatic cancer cell line are largely quiescent, and enriched in Mirk/dyrk1B kinase, the quiescence protein p130/Rb2 and the CDK inhibitor p27. Treatment with two novel Mirk/dyrk1B kinase inhibitors led to a decrease in spheroid quiescence markers, and up to a 7-fold decrease in spheroid volume and viable cell numbers. Significantly, Mirk is expressed in patient-derived ovarian cancer ascites spheroids, and ascites treatment with the most potent Mirk/dyrk1B kinase inhibitor led first to an induction of apoptosis markers, then to a disruption of spheroid structure, and finally to a 90% loss in viable tumor cells. This inhibitor, at concentrations that killed patient-derived ovarian cancer ascites spheroid cells in vitro, had no detectable toxicity in mice, not decreasing mouse weight, but reduced the size of Panc1 xenografts up to 3-fold, while increasing the percent of Ki67 positive tumor cells. Both observations were consistent with the model that Mirk/dyrk1B kinase inhibition allowed quiescent tumor cells to enter cycle prematurely where they would die.
Citation Format: Xiaobing Deng, Jing Hu, Mary Cunningham, Bertrand Leblond, Thierry Besson, Anne-Sophie Casagrande, Laurent Désiré, Eileen A. Friedman. Mirk/dyrk1B kinase inhibitor reduces the viability of patient-derived ovarian cancer ascites cells and the size of murine tumor xenografts. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2164. doi:10.1158/1538-7445.AM2013-2164
Collapse
Affiliation(s)
| | - Jing Hu
- 1SUNY Upstate Medical Univ., Syracuse, NY
| | | | | | | | | | | | | |
Collapse
|
47
|
Casagrande AS, Bachelot F, Coutadeur S, Leblond B, Besson T, Pando MP, Désiré L. Abstract 2165: Structure activity relationship of a novel chemical class of Dyrk inhibitors. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-2165] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Dual-specificity tyrosine-phosphorylated and regulated kinases (DYRK) is a family of conserved protein kinases which mediate survival and differentiation in normal tissues like skeletal muscle for Mirk/Dyrk1B or neuronal cells for Dyrk1A. Among the five Dyrk proteins, Mirk/Dyrk1B has very low level of expression in most normal cell types but has been found to be upregulated in solid tumors and to mediate cell survival in colon cancer, pancreatic ductal adenocarcinoma, rhabdomyosarcomas, lung and ovarian cancer. Mirk/Dyrk1B expression and abundance varies during the cell cycle with the highest levels found in quiescent G0 phase where it mediates G0 tumor cells prolonged survival (through increasing expression of a cohort of antioxidant genes). Dyrk1A also promotes quiescence and senescence through DREAM complex assembly by phosphorylating the DREAM subunit LIN52. The ability of cells to exit from the cell cycle and enter into the G0 or quiescence state is important for cell differentiation, tissue development, and prevention of tumorigenesis. Tumors may contain a fraction of quiescent cells responsible for resistance to chemotherapy and radiation, serving as a reservoir for tumor repopulation post-therapy. Thus, pharmacological Dyrk inhibition would reduce the ability of cells to enter into quiescence and sensitize cancer cells to conventional chemotherapeutic agents. Exonhit has developed a novel class of DYRK inhibitors. Lead optimization led to the synthesis of new chemical entities with subnanomolar kinase inhibitory activities associated with a high degree of selectivity over 400 kinases. Most active compounds were evaluated in various cellular models, demonstrating good correlation between cellular activity and amplification/expression of Mirk/Dyrk1B. Similarly, in accordance with the expression levels of Mirk/Dyrk1B during the cell cycle, cellular potency of pharmacological inhibitors was improved 3 to 11 fold in SW620 quiescent cultures when compared to cycling cultures. We analyzed the effects of Dyrk inhibitors alone and in combination with gemcitabine in the Panc1 pancreatic cancer cell line multicellular tumor spheroid model described to be largely quiescent and enriched in Mirk/Dyrk1B kinase and confirmed that Dyrk inhibitors sensitize cells to gemcitabine with a synergistic effect of the combination. Among the 120 NCEs from this series, we identified lead compounds having potent in vitro efficacy as Dyrk inhibitors. These compounds are being further characterized in various cellular studies and show promising in vivo activities in patient-derived ovarian cancer ascites spheroids and Panc1 xenografts model without detectable toxicity in mice, establishing the usefulness of these inhibitors for targeting cancer cells with high Dyrk kinase activity.
Citation Format: Anne-Sophie Casagrande, Florence Bachelot, Séverine Coutadeur, Bertrand Leblond, Thierry Besson, Matthew P. Pando, Laurent Désiré. Structure activity relationship of a novel chemical class of Dyrk inhibitors. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2165. doi:10.1158/1538-7445.AM2013-2165
Collapse
|
48
|
Guillon R, Pagniez F, Picot C, Hédou D, Tonnerre A, Chosson E, Duflos M, Besson T, Logé C, Le Pape P. Discovery of a novel broad-spectrum antifungal agent derived from albaconazole. ACS Med Chem Lett 2013; 4:288-92. [PMID: 24900660 DOI: 10.1021/ml300429p] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2012] [Accepted: 01/17/2013] [Indexed: 11/29/2022] Open
Abstract
Synthesis of a strict structural analogue of albaconazole in which the quinazolinone ring is fused by a thiazole moiety led to the discovery of a new triazole with broad-spectrum antifungal activity. Compound I exhibited high in vitro activity against pathogenic Candida species and filamentous fungi and showed preliminary in vivo antifungal efficacy in a mice model of systemic candidiasis.
Collapse
Affiliation(s)
- Rémi Guillon
- Université de Nantes, Nantes Atlantique Universités, Laboratoire
de Chimie Thérapeutique, Cibles et Médicaments des Infections
et du Cancer, IICIMED-EA 1155, UFR Sciences Pharmaceutiques, 1 rue
Gaston Veil, Nantes F-44035 Cedex 1, France
| | - Fabrice Pagniez
- Université de Nantes, Nantes Atlantique Universités, Laboratoire
de Parasitologie et Mycologie Médicale, Cibles et Médicaments
des Infections et du Cancer, IICIMED-EA 1155, UFR Sciences Pharmaceutiques,
1 rue Gaston Veil, Nantes F-44035 Cedex 1, France
| | - Carine Picot
- Université de Nantes, Nantes Atlantique Universités, Laboratoire
de Parasitologie et Mycologie Médicale, Cibles et Médicaments
des Infections et du Cancer, IICIMED-EA 1155, UFR Sciences Pharmaceutiques,
1 rue Gaston Veil, Nantes F-44035 Cedex 1, France
| | - Damien Hédou
- Université de Rouen, Laboratoire C.O.B.R.A., CNRS UMR 6014 & FR 3038, Institut de Recherche en Chimie Organique Fine (I.R.C.O.F.), rue Tesnière, 76130 Mont Saint-Aignan, France
| | - Alain Tonnerre
- Université de Nantes, Nantes Atlantique Universités, Laboratoire
de Chimie Thérapeutique, Cibles et Médicaments des Infections
et du Cancer, IICIMED-EA 1155, UFR Sciences Pharmaceutiques, 1 rue
Gaston Veil, Nantes F-44035 Cedex 1, France
| | - Elizabeth Chosson
- Université de Rouen, Laboratoire C.O.B.R.A., CNRS UMR 6014 & FR 3038, Institut de Recherche en Chimie Organique Fine (I.R.C.O.F.), rue Tesnière, 76130 Mont Saint-Aignan, France
| | - Muriel Duflos
- Université de Nantes, Nantes Atlantique Universités, Laboratoire
de Chimie Thérapeutique, Cibles et Médicaments des Infections
et du Cancer, IICIMED-EA 1155, UFR Sciences Pharmaceutiques, 1 rue
Gaston Veil, Nantes F-44035 Cedex 1, France
| | - Thierry Besson
- Université de Rouen, Laboratoire C.O.B.R.A., CNRS UMR 6014 & FR 3038, Institut de Recherche en Chimie Organique Fine (I.R.C.O.F.), rue Tesnière, 76130 Mont Saint-Aignan, France
| | - Cédric Logé
- Université de Nantes, Nantes Atlantique Universités, Laboratoire
de Chimie Thérapeutique, Cibles et Médicaments des Infections
et du Cancer, IICIMED-EA 1155, UFR Sciences Pharmaceutiques, 1 rue
Gaston Veil, Nantes F-44035 Cedex 1, France
| | - Patrice Le Pape
- Université de Nantes, Nantes Atlantique Universités, Laboratoire
de Parasitologie et Mycologie Médicale, Cibles et Médicaments
des Infections et du Cancer, IICIMED-EA 1155, UFR Sciences Pharmaceutiques,
1 rue Gaston Veil, Nantes F-44035 Cedex 1, France
| |
Collapse
|
49
|
Loidreau Y, Levacher V, Besson T. Suzuki cross-coupling of 5-bromothieno[2,3-b]pyridines for the convenient synthesis of 8-arylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-amines. Tetrahedron Lett 2013. [DOI: 10.1016/j.tetlet.2012.12.077] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
50
|
Loidreau Y, Marchand P, Dubouilh-Benard C, Nourrisson MR, Duflos M, Loaëc N, Meijer L, Besson T. Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases. Eur J Med Chem 2013; 59:283-95. [PMID: 23237976 DOI: 10.1016/j.ejmech.2012.11.030] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2012] [Revised: 11/12/2012] [Accepted: 11/19/2012] [Indexed: 01/04/2023]
Abstract
Novel N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines (1) and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues (2) were designed and prepared for the first time via microwave-accelerated multi-step synthesis. Various anilines were condensed with N'-(2-cyanaryl)-N,N-dimethylformimidamide intermediates obtained by reaction of 3-amino-6-methoxybenzofuran-2-carbonitrile (3) and 3-amino-6-methoxybenzothiophene-2-carbonitrile (4) precursors with dimethylformamide dimethylacetal. The inhibitory potency of the final products against five protein kinases (CDK5/p25, CK1δ/ε, GSK3α/β, DYRK1A and CLK1) was estimated. Compounds (2a-z) turned out to be particularly promising for the development of new pharmacological dual inhibitors of CLK1 and DYRK1A kinases.
Collapse
Affiliation(s)
- Yvonnick Loidreau
- Université de Rouen, Laboratoire de Chimie Organique et Bio-organique, Réactivité et Analyse (C.O.B.R.A.), CNRS UMR 6014 & FR3038, Institut de Recherche en Chimie Organique Fine (I.R.C.O.F.) rue Tesnière, 76130 Mont Saint-Aignan, France
| | | | | | | | | | | | | | | |
Collapse
|